26 June 2020
A new PolicyBristol briefing brings together evidence from a range of research projects investigating strategies to reduce Hepatitis C transmission among people who inject drugs.
The briefing, “Cost effective tools to reduce the spread of the Hepatitis C virus in people who inject drugs”, brings together evidence from a number of research projects using a variety of research methods, including:
Worldwide, an estimated 71 million people live with Hepatitis C (HCV). Most new infections in the UK and other similar countries are amongst people who inject drugs. NHS England has set a target to eliminate HCV as a public health threat by 2025.
Matthew Hickman, Professor in Public Health and Epidemiology, University of Bristol, who led the research, said:
“It’s vital that local and national government have evidence on the effectiveness and cost-effectiveness of public health interventions, to justify investment and ensure key services are maintained. Our work shows that needle and syringe programmes in general and distribution of low dead space syringes are not only cost-effective but can also be cost saving in relation to prevention of Hepatitis C and HCV-related liver disease. We show also how changes to injecting equipment can be successfully implemented in practice, through co-producing health advice to services and service users.”
The policy report outlines the key findings and implications of the research for policy makers, which include:
If you would like to find out more about this research or discuss the implications, please contact Dr Clare Thomas, Research Fellow in the National Institute for Health Research (NIHR) Health Protection Research Unit in Behavioural Science and Evaluation, University of Bristol and the NIHR Applied Research Collaboration West (email@example.com).
PolicyBristol is hosting a webinar: “Drugs, data, harm reduction and human rights” on 2 July from 2pm to 4pm. Register via Eventbrite